The aftermath of the Merck's HIV vaccine trial

Retrovirology

Volumn 5, Issue , 2008, Pages

  Iaccino, Enrico ^a   Schiavone, Marco ^b   Fiume, Giuseppe ^a   Quinto, Ileana ^a,b   Scala, Giuseppe ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; VIRUS VECTOR;

ADENOVIRUS 5; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; LYMPHOCYTE ACTIVATION; OUTCOME ASSESSMENT; SCORING SYSTEM; T LYMPHOCYTE; VIRUS LOAD; VOLUNTEER; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 48449090498     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-5-56     Document Type: Article

References (42)

1. Press Releases - HIV Vaccine Trials Network http://www.hvtn.org/media/pr/ step111307.html
2. Mattapallil JJ Douek DC Hill B Nishimura Y Martin M Roederer M Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection Nature 2005, 434:1093-1097 15793563
3. Jeeninga RE Westerhout EM van Gerven ML Berkhout B HIV-1 latency in actively dividing human T cell lines Retrovirology 2008, 5:37 2387167 18439275
4. Schiavone M Quinto I Scala G Perspectives for a protective HIV-1 vaccine Adv Pharmacol 2008, 56:423-452 18086420
5. Wu Y HIV-1 gene expression: Lessons from provirus and non-integrated DNA Retrovirology 2004, 1:13 449739 15219234
6. Marcello A Latency: The hidden HIV-1 challenge Retrovirology 2006, 3:7 1379657 16412247
7. Sun Y Permar SR Buzby AP Letvin NL Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection J Virol 2007, 81:8009-8015 1951297 17522197
8. Li Q Duan L Estes JD Ma ZM Rourke T Wang Y Reilly C Carlis J Miller CJ Haase AT Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells Nature 2005, 434:1148-1152 15793562
9. Chun TW Nickle DC Justement JS Meyers JH Roby G Hallahan CW Kottilil S Moir S Mican JM Mullins JI Ward DJ Kovacs JA Mannon PJ Fauci AS Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy J Infect Dis 2008, 197(5):714-720 18260759
10. Champagne P Ogg GS King AS Knabenhans C Ellefsen K Nobile M Appay V Rizzardi GP Fleury S Lipp M Forster R Rowland-Jones S Sékaly RP McMichael AJ Pantaleo G Skewed maturation of memory HIV-specific CD8 T lymphocytes Nature 2001, 410:106-111 11242051
11. Barouch DH Kunstman J Kuroda MJ Schmitz JE Santra S Peyerl FW Krivulka GR Beaudry K Lifton MA Gorgone DA Montefiori DC Lewis MG Wolinsky SM Letvin NL Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes Nature 2002, 415:335-339 11797012
12. Barouch DH Letvin NL HIV escape from cytotoxic T lymphocytes: A potential hurdle for vaccines? Lancet 2004, 364:10-11 15234837
13. Chen X Scala G Quinto I Liu W Chun TW Justement JS Cohen OJ vanCott TC Iwanicki M Lewis MG Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes Nat Med 2001, 7:1225-1231 11689887
14. Guadalupe M Reay E Sankaran S Prindiville T Flamm J McNeil A Dandekar S Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy J Virol 2003, 77:11708-11717 229357 14557656
15. O'Connor DH Burton DR Immune responses and HIV: A little order from the chaos J Exp Med 2006, 203:501-503 2118239 16533889
16. Richman DD Wrin T Little SJ Petropoulos CJ Rapid evolution of the neutralizing antibody response to HIV type 1 infection Proc Natl Acad Sci USA 2003, 100:4144-4149 153062 12644702
17. Loh L Petravic J Batten CJ Davenport MP Kent SJ Vaccination and timing influence SIV immune escape viral dynamics in vivo PLoS Pathog 2008, 4:e12 2323283 18225952
18. Frost SD Liu Y Pond SL Chappey C Wrin T Petropoulos CJ Little SJ Richman DD Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B J Virol 2005, 79:6523-6527 1091710 15858036
19. Hessell AJ Hangartner L Hunter M Havenith CE Beurskens FJ Bakker JM Lanigan CM Landucci G Forthal DN Parren PW Marx PA Burton DR Fc receptor but not complement binding is important in antibody protection against HIV Nature 2007, 449:101-104 17805298
20. Wei X Decker JM Wang S Hui H Kappes JC Wu X Salazar-Gonzalez JF Salazar MG Kilby JM Saag MS Komarova NL Nowak MA Hahn BH Kwong PD Robinson JE Shaw GM Antibody neutralization and escape by HIV-1 Nature 2003, 422:307-312 12646921
21. Busch M Abel K Li J Piatak M Jr Lifson JD Miller CJ Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge Vaccine 2005, 23:4036-4047 15963361
22. Barnett SW Srivastava IK Kan E Zhou F Goodsell A Cristillo AD Ferrai MG Weiss DE Letvin NL Montefiori D Pal R Vajdy M Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope Aids 2008, 22:339-348 18195560
23. Barouch DH Kunstman J Glowczwskie J Kunstman KJ Egan MA Peyerl FW Santra S Kuroda MJ Schmitz JE Beaudry K Krivulka GR Lifton MA Gorgone DA Wolinsky SM Letvin NL Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys J Virol 2003, 77:7367-7375 164797 12805435
24. Leslie AJ Pfafferott KJ Chetty P Draenert R Addo MM Feeney M Tang Y Holmes EC Allen T Prado JG Altfeld M Brander C Dixon C Ramduth D Jeena P Thomas SA St John A Roach TA Kupfer B Luzzi G Edwards A Taylor G Lyall H Tudor-Williams G Novelli V Martinez-Picado J Kiepiela P Walker BD Goulder PJ HIV evolution: CTL escape mutation and reversion after transmission Nat Med 2004, 10:282-289 14770175
25. Shibata R Igarashi T Haigwood N Buckler-White A Ogert R Ross W Willey R Cho MW Martin MA Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys Nat Med 1999, 5:204-210 9930869
26. Mascola JR Stiegler G VanCott TC Katinger H Carpenter CB Hanson CE Beary H Hayes D Frankel SS Birx DL Lewis MG Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies Nat Med 2000, 6:207-210 10655111
27. Parren PW Marx PA Hessell AJ Luckay A Harouse J Cheng-Mayer C Moore JP Burton DR Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro J Virol 2001, 75:8340-8347 115078 11483779
28. Gilbert PB Peterson ML Follmann D Hudgens MG Francis DP Gurwith M Heyward WL Jobes DV Popovic V Self SG Sinangil F Burke D Berman PW Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial J Infect Dis 2005, 191:666-677 15688279
29. Berman PW Development of bivalent rgp120 vaccines to prevent HIV type 1 infection AIDS Res Hum Retroviruses 1998, 14(Suppl 3):S277-289 9814956
30. Berman PW Huang W Riddle L Gray AM Wrin T Vennari J Johnson A Klaussen M Prashad H Köhne C deWit C Gregory TJ Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand Virology 1999, 265:1-9 10603312
31. Rasmussen RA Montefiori DC Robinson HL McClure HM Ruprecht RM Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: Lack of original antigenic sin J Infect Dis 2001, 184:1603-1607 11740737
32. Cho MW Kim YB Lee MK Gupta KC Ross W Plishka R Buckler-White A Igarashi T Theodore T Byrum R Kemp C Montefiori DC Martin MA Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques J Virol 2001, 75:2224-2234 114806 11160726
33. Shiver JW Fu TM Chen L Casimiro DR Davies ME Evans RK Zhang ZQ Simon AJ Trigona WL Dubey SA Huang L Harris VA Long RS Liang X Handt L Schleif WA Zhu L Freed DC Persaud NV Guan L Punt KS Tang A Chen M Wilson KA Collins KB Heidecker GJ Fernandez VR Perry HC Joyce JG Grimm KM Cook JC Keller PM Kresock DS Mach H Troutman RD Isopi LA Williams DM Xu Z Bohannon KE Volkin DB Montefiori DC Miura A Krivulka GR Lifton MA Kuroda MJ Schmitz JE Letvin NL Caulfield MJ Bett AJ Youil R Kaslow DC Emini EA Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity Nature 2002, 415:331-335 11797011
34. Barouch DH Santra S Schmitz JE Kuroda MJ Fu TM Wagner W Bilska M Craiu A Zheng XX Krivulka GR Beaudry K Lifton MA Nickerson CE Trigona WL Punt K Freed DC Guan L Dubey S Casimiro D Simon A Davies ME Chastain M Strom TB Gelman RS Montefiori DC Lewis MG Emini EA Shiver JW Letvin NL Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination Science 2000, 290:486-492 11039923
35. Montefiori D Sattentau Q Flores J Esparza J Mascola J Antibody-based HIV-1 vaccines: Recent developments and future directions PLoS Med 2007, 4:e348 2100141 18052607
36. Dubey S Clair J Fu TM Guan L Long R Mogg R Anderson K Collins KB Gaunt C Fernandez VR Zhu L Kierstead L Thaler S Gupta SB Straus W Mehrotra D Tobery TW Casimiro DR Shiver JW Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay J Acquir Immune Defic Syndr 2007, 45:20-27 17310936
37. Goepfert PA Horton H McElrath MJ Gurunathan S Ferrari G Tomaras GD Montefiori DC Allen M Chiu YL Spearman P Fuchs JD Koblin BA Blattner WA Frey S Keefer MC Baden LR Corey L NIAID HIV Vaccine Trials Network High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects J Infect Dis 2005, 192:1249-1259 16136469
38. Russell ND Graham BS Keefer MC McElrath MJ Self SG Weinhold KJ Montefiori DC Ferrari G Horton H Tomaras GD Gurunathan S Baglyos L Frey SE Mulligan MJ Harro CD Buchbinder SP Baden LR Blattner WA Koblin BA Corey L National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: Negative results fail to trigger a phase 3 correlates trial J Acquir Immune Defic Syndr 2007, 44:203-212 2362395 17106277
39. Harari A Bart PA Stöhr W Tapia G Garcia M Medjitna-Rais E Burnet S Cellerai C Erlwein O Barber T Moog C Liljestrom P Wagner R Wolf H Kraehenbuhl JP Esteban M Heeney J Frachette MJ Tartaglia J McCormack S Babiker A Weber J Pantaleo G An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses J Exp Med 2008, 205:63-77 18195071
40. HIV Vaccine Trials Network - Working to prevent AIDS http://www.hvtn.org
41. Global Health Program - Bill & Melinda Gates Foundation http://www.gatesfoundation.org/GlobalHealth
42. Koski G Nightingale SL Research involving human subjects in developing countries N Engl J Med 2001, 345:136-138 11450664